• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMD Serono makes key oncology appointments

EMD Serono makes key oncology appointments

May 28, 2015
CenterWatch Staff

EMD Serono, the U.S. biopharmaceutical business of Germany’s Merck, has announced two critical management appointments to lead its entry into oncology. EMD Serono's diversified oncology and immuno-oncology pipeline includes multiple, high-priority projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient need.

David Trexler, senior vice president of oncology commercial, will lead the strategy of the EMD Serono oncology franchise and will be responsible for maximizing growth opportunities by building a performance-driven oncology team focused on customer and patient centricity.

Trexler has more than 25 years of experience in branded pharmaceutical marketing, sales and business development. He joins EMD Serono from Eisai, where he was senior vice president of the americas oncology business unit. At Eisai, Trexler successfully led the oncology sales and marketing teams, expanding Eisai's reach in strategic markets across the Americas. Trexler previously held senior leadership roles at Mylan Bertek Pharmaceuticals and Sanofi-Aventis Pharmaceuticals.

Dr. Zhen Su, vice president of oncology medical, will lead the medical strategy and team for the franchise. A physician executive with more than 15 years of experience, Su has strong clinical experience in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development.

Previosuly, Su was associate vice president and global head of Jevtana (cabazitaxel) at Sanofi. Su also has held several academic positions, including assistant professor of Surgery at Duke University, where he received his fellowship in oncology.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing